Teva names new CEO

Share this article:

The rumors are true: Erez Vigodman is Teva Pharmaceutical's new president and CEO. The Jerusalem, Israel, company said in the Thursday announcement that he will officially take on the roles February 11.

The appointment will end a public relations rough patch which included the October announcement that Teva was laying off 10% of its staff to limit the impact of generic Copaxone, which was soon followed by a public “was he fired or was he pushed?” feud that saw then-CEO Jeremy Levin leave the company. Eyal Desheh stepped in as acting president and CEO. He will now slide back into his role as group EVP and CFO.

Vigodman was already on Teva's board and currently heads up the generic agrochemical company Makhteshim Agan Industries. Teva said in a statement that Vigodman will stay with MAI until February 6.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.